LGND Stock Charts

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31

cash flows from operating activities:
net income	117,273,000	4,847,000	-42,451,000	-31,088,000	-7,172,000	-51,911,000	86,139,000	18,188,000	-10,273,000	2,290,000	41,949,000	-17,485,000	404,000	-895,000	-15,385,000	-5,416,000	13,723,000	5,761,000	-6,701,000	22,086,000	-24,131,000	-7,365,000	-15,251,000	-14,419,000	666,337,000	-42,482,000	67,362,000	73,162,000	45,279,000	-7,010,000	8,429,000	6,058,000	5,079,000												2,097,000	1,869,000	1,965,000	6,091,000	1,495,000	1,063,000	-707,000	-2,267,000	1,384,000	5,502,000	-3,902,000	-914,000	9,490,000	4,503,000	-11,842,000	-284,000	-2,750,000	3,036,000	1,800,000	-1,668,000	-5,116,000	-69,627,000	-18,125,000	-6,429,000	-3,933,000	5,938,000	1,248,000	181,000	274,321,000	141,364,000	-14,920,000	-15,958,000	-142,229,000	-2,722,000	-6,281,000	-8,924,000	-18,472,000	-14,216,000	-13,139,000	5,943,000	-11,088,000	-11,997,000	-20,320,000	-6,728,000
adjustments to reconcile net income to net cash from operating activities:
change in estimated fair value of contingent liabilities	-456,000	52,000	1,879,000	-310,000	-207,000	1,233,000	-33,000	-397,000	24,000	778,000	-670,000	630,000	-112,000	-231,000	-1,035,000	2,415,000	-5,875,000	1,360,000	-26,000	1,000	-372,000
depreciation of fixed assets and amortization of intangible assets	8,269,000	8,522,000	8,770,000
accretion of short-term investments	-1,338,000
amortization of debt discount and issuance fees	447,000	125,000	136,000	172,000	134,000	96,000	84,000	81,000	0	64,000	95,000	95,000	138,000	175,000	326,000	3,829,000	3,790,000	5,334,000	5,301,000	5,239,000	7,203,000	7,426,000	7,563,000	7,553,000	7,446,000	18,799,000	9,700,000	12,437,000	3,018,000	2,972,000	2,927,000	2,882,000	2,838,000	2,795,000	2,752,000	2,710,000	2,668,000	2,628,000	2,588,000	2,549,000	2,509,000	2,471,000
non-cash income from financial royalty assets	-360,000	-427,000	-461,000	-780,000
cecl adjustment to financial royalty assets	26,000	-420,000	-330,000	-852,000	797,000	-1,419,000	-2,841,000
impairment loss of financial royalty assets				4,081,000	0
gain on pelthos transaction
loss on derivative instruments
income from equity method investment in primrose bio
(gain) income from change in fair value of equity-method investments and other investments
share-based compensation	14,746,000	9,997,000	7,836,000	7,524,000	15,171,000	11,060,000	7,334,000	5,721,000	6,884,000	7,207,000	5,931,000	29,145,000	12,597,000	9,499,000	9,044,000	10,408,000	9,754,000	9,975,000	7,740,000	7,359,000	5,653,000	6,300,000	6,297,000	6,571,000	5,347,000	6,009,000																					1,533,000	1,492,000	1,124,000		1,013,000
deferred income taxes	21,282,000	-325,000	-8,844,000	-12,692,000	-1,988,000	-20,666,000	19,546,000	4,935,000	8,007,000	-10,000,000	8,754,000	46,293,000	-12,645,000	3,255,000	-16,180,000	-389,000	1,537,000	258,000	-10,421,000	1,529,000	-10,419,000	17,063,000	2,105,000	-6,602,000	62,263,000	-14,410,000	11,886,000	22,401,000	9,862,000	37,663,000	3,631,000	2,206,000	1,018,000	10,350,000	160,000	-3,914,000	4,101,000	-2,624,000	-217,257,000	262,000	6,000	294,000	110,000	-47,000	53,000	137,000	61,000	110,000	66,000	-1,650,000	143,000	338,000	-35,000	503,000	23,000	125,000	-13,908,000
gain from short-term investments	-7,798,000	-939,000	12,367,000	31,022,000	-2,407,000	14,256,000	-110,772,000						923,000	1,909,000	12,877,000		-1,938,000
lease amortization expense	479,000	412,000	571,000	571,000	573,000	504,000	478,000	504,000	334,000	450,000	447,000	986,000	1,481,000
other	205,000	821,000	915,000	4,600,000	2,765,000	568,000	-210,000	524,000	62,000	-87,000	240,000	410,000	22,000	13,000	-80,000	914,000	63,000	4,182,000	-26,000	-7,167,000	5,668,000	-207,000	2,724,000	1,157,000	-5,130,000		3,452,000	106,000	-522,000		1,000,000										-1,000						0	0	-13,000	144,000	127,000	136,000	85,000	90,000	93,000	73,000	29,000	0	5,000	-10,000	37,000	-14,000	1,000	-23,000	19,000	-24,000	21,000	-8,000	-5,000	163,000	-22,000	-10,000	356,000	-163,000	1,000	-9,000	-8,000	56,000	27,000	24,000	28,000	25,000	39,000	39,000	28,000	477,000	70,000	-119,000
changes in operating assets and liabilities, net of acquisition:
accounts receivable	-16,309,000	-2,765,000	-576,000	-5,665,000	4,793,000	-9,049,000	3,462,000	2,835,000	-7,912,000	1,377,000	1,099,000	34,769,000	-2,658,000	-20,430,000	43,638,000	-19,778,000	-6,179,000	-20,981,000	6,386,000	-3,068,000	-8,398,000	-8,429,000	-1,699,000	6,356,000	29,235,000	-8,164,000	-4,975,000	-4,893,000	-11,512,000	-10,267,000	646,000	-6,380,000	7,643,000	-8,114,000	3,380,000	1,813,000	-5,604,000	-653,000	40,000	1,891,000	5,211,000	-6,822,000	-2,679,000	1,540,000	-2,451,000	3,285,000	-4,808,000	3,923,000	-33,000	-2,432,000	-1,340,000	1,175,000	4,118,000	-4,391,000	-681,000	133,000	1,024,000	-898,000	-95,000	298,000	320,000	1,492,000	-1,060,000	1,665,000	-2,715,000					14,000	36,000	1,219,000	10,268,000	-4,444,000	11,590,000	1,379,000	908,000	3,424,000	-3,362,000	-2,692,000	12,523,000	-3,751,000	4,866,000	-9,128,000	-2,234,000	9,397,000	-4,910,000	-355,000
inventory	3,589,000	-875,000	-500,000	2,566,000	1,932,000	2,489,000	2,632,000	707,000	-611,000	-13,001,000	2,035,000	1,356,000	962,000	9,696,000	44,000	2,676,000	-777,000	-12,885,000	-11,891,000	5,726,000	1,251,000	-561,000	3,073,000	-1,750,000	-2,823,000	1,204,000	632,000	583,000	-4,978,000	1,142,000	2,301,000	-3,089,000	-1,197,000	2,150,000	-192,000	-3,055,000	853,000	-243,000	375,000	-383,000	-150,000	4,048,000	-254,000	1,132,000	-557,000	560,000	-343,000	327,000	102,000	1,828,000	-493,000	-261,000	-44,000	659,000	634,000	1,618,000	-1,797,000
accounts payable and accrued liabilities	1,093,000	-407,000	-2,149,000	11,286,000	2,227,000	1,772,000	-1,382,000	2,757,000	-2,501,000	-4,525,000	-435,000	-2,935,000	3,952,000	-1,649,000	-2,708,000	6,445,000	705,000	-11,139,000	6,985,000	795,000	2,114,000	-3,452,000	406,000	-1,904,000	-1,876,000				321,000	936,000	-496,000	-190,000	-1,963,000	710,000	244,000	979,000	-4,302,000	966,000	-1,886,000	1,560,000	-4,667,000	323,000	265,000	-2,741,000	-1,002,000	-452,000	287,000	-495,000	-2,098,000	-1,792,000	642,000	-145,000	-3,506,000	-5,150,000	1,765,000	-7,755,000	-428,000	788,000	-6,203,000	1,778,000	-9,810,000	-3,053,000	5,084,000	-523,000	-12,497,000	5,881,000	-7,505,000	-1,305,000	-4,409,000	-6,859,000	-11,377,000	-20,665,000	-12,988,000	-21,887,000	-8,627,000	17,786,000	-14,912,000	11,401,000	6,406,000	-3,162,000	-958,000	4,163,000	3,164,000	10,512,000	9,321,000	-1,943,000	6,629,000	3,430,000
income tax receivable and payable	864,000	2,423,000	335,000		-9,093,000	953,000	7,533,000		-10,183,000	11,387,000	4,614,000		6,100,000	-2,982,000	11,993,000		-1,690,000
deferred revenue	0	-285,000	-293,000	-136,000	-232,000	-400,000	-540,000	193,000			-98,000	-1,099,000	-2,928,000	199,000	-2,453,000	2,826,000	-6,091,000																	-1,505,000	1,384,000	100,000	13,000	-2,109,000	-8,000	-27,000	-83,000	82,000	22,000	92,000	-116,000	-220,000	-116,000	-144,000	-174,000	-141,000	-138,000	-963,000	-609,000	3,406,000	-29,000	-1,244,000	27,000	0	-2,663,000	-1,660,000	-1,615,000	-7,306,000	-2,890,000	-1,892,000	-2,214,000					0	0	0	-8,657,000	-22,121,000	-35,979,000	-7,943,000	-6,576,000	-782,000	4,774,000	357,000	332,000	-43,000	-295,000	-1,015,000	-702,000	-790,000	-351,000	-2,188,000
other assets and liabilities	148,000	-4,262,000	-1,985,000	634,000	7,494,000	-3,375,000	-3,462,000	-8,966,000	-769,000	-812,000	682,000	8,013,000	-417,000	-1,021,000	-233,000		-5,894,000
net cash from operating activities	13,090,000	15,799,000	-25,445,000	28,471,000	36,530,000	13,314,000	18,732,000	8,065,000	7,646,000	-82,000	33,948,000	53,472,000	20,489,000	11,878,000	52,011,000	27,642,000	20,025,000				16,922,000	-7,339,000	-6,197,000	-61,058,000	45,258,000	32,572,000	27,082,000	73,644,000	60,761,000	31,310,000	27,650,000	10,386,000	24,222,000	20,993,000	18,523,000	10,371,000	13,114,000	13,665,000	10,437,000	10,046,000	7,579,000	10,246,000	3,735,000	4,008,000	2,577,000	12,034,000	-359,000	6,937,000	2,078,000	2,172,000	-910,000	-732,000	-369,000	7,017,000	-1,055,000	-8,045,000	911,000	-1,300,000	-7,674,000	-2,217,000	-15,876,000	-1,289,000	-11,341,000	2,950,000	-24,121,000	6,193,000	-13,448,000	-3,971,000	-9,399,000	-8,787,000	-14,231,000	-29,360,000	-45,349,000	-84,069,000	-28,021,000	-6,447,000	-19,984,000	12,072,000	6,795,000	-7,905,000	-2,597,000	-11,636,000	-3,616,000	9,176,000	-2,611,000	3,456,000	-9,747,000	-9,562,000
capex	-15,000	-214,000	-214,000	0	-596,000	-408,000	-105,000	0	-487,000	-203,000	-2,414,000	0	-4,329,000	-6,588,000	-4,875,000	0	-1,772,000				0	0	0	0	0	0	0	0	0	-1,936,000	-21,000	-112,000	-87,000	-67,000	-762,000	-783,000	-238,000	-66,000	0	-17,000	-10,000	0	0	0	-6,000	0	-105,000	-121,000	-37,000	38,000	-372,000	-242,000	-19,000	0	0	0	-5,000	0	-5,000	-9,000	-56,000	15,000	-217,000	-106,000	-214,000	-41,000	-69,000	-189,000	-196,000	-71,000	-38,000	-245,000	-86,000	-191,000	-918,000	-484,000	-190,000	-826,000	-625,000	-548,000	-597,000	-1,069,000	-952,000	-1,542,000	-796,000	-207,000	-238,000	-281,000
free cash flows	13,075,000	15,585,000	-25,659,000	28,471,000	35,934,000	12,906,000	18,627,000	8,065,000	7,159,000	-285,000	31,534,000	53,472,000	16,160,000	5,290,000	47,136,000	27,642,000	18,253,000				16,922,000	-7,339,000	-6,197,000	-61,058,000	45,258,000	32,572,000	27,082,000	73,644,000	60,761,000	29,374,000	27,629,000	10,274,000	24,135,000	20,926,000	17,761,000	9,588,000	12,876,000	13,599,000	10,437,000	10,029,000	7,569,000	10,246,000	3,735,000	4,008,000	2,571,000	12,034,000	-464,000	6,816,000	2,041,000	2,210,000	-1,282,000	-974,000	-388,000	7,017,000	-1,055,000	-8,045,000	906,000	-1,300,000	-7,679,000	-2,226,000	-15,932,000	-1,274,000	-11,558,000	2,844,000	-24,335,000	6,152,000	-13,517,000	-4,160,000	-9,595,000	-8,858,000	-14,269,000	-29,605,000	-45,435,000	-84,260,000	-28,939,000	-6,931,000	-20,174,000	11,246,000	6,170,000	-8,453,000	-3,194,000	-12,705,000	-4,568,000	7,634,000	-3,407,000	3,249,000	-9,985,000	-9,843,000
cash flows from investing activities:
acquisition of financial royalty assets	-8,391,000	0	-1,821,000	0
acquisition of royalty receivables
proceeds from financial royalty assets	3,587,000	2,030,000	3,149,000	2,537,000	685,000	2,265,000	1,942,000
purchases of derivatives			-7,620,000
purchases of property and equipment	-15,000	-214,000	-214,000																											-1,936,000	-21,000	-112,000	-87,000	-67,000	-762,000	-783,000	-238,000	-66,000	0	-17,000	-10,000				-6,000		-105,000	-121,000	-37,000							0	-5,000	0	-5,000	-9,000	-56,000	15,000	-217,000	-106,000	-214,000	-41,000	-69,000	-189,000	-196,000	-71,000	-38,000	-245,000	-86,000	-191,000	-918,000	-484,000	-190,000	-826,000	-625,000	-548,000	-597,000	-1,069,000	-952,000	-1,542,000	-796,000	-207,000	-238,000	-281,000
purchases of short-term investments	-392,139,000	-63,343,000	-59,374,000																																																			0	0	-5,000,000	-5,000,000	-1,791,000	-1,932,000	0	-31,861,000	0	0	-21,549,000	-11,257,000	-5,997,000	-3,515,000	-36,257,000	-22,601,000	-1,939,000	-17,065,000			-59,000	-5,630,000	-7,968,000	-4,726,000	-1,203,000	-3,404,000	-3,424,000	-21,425,000	-17,505,000	-8,375,000	-27,149,000	-378,000	-168,000	-331,000	-4,178,000
proceeds from sale of short-term investments	185,000	0	38,414,000	39,804,000	90,655,000	37,989,000	60,919,000	52,447,000	7,486,000	44,600,000	44,232,000	7,009,000	24,998,000	44,688,000	132,866,000	1,765,000	1,817,000	5,243,000	209,865,000	0	179,431,000	391,695,000	100,458,000	43,383,000	341,000	55,949,000	63,202,000	500,000	12,291,000	3,595,000	122,000	65,549,000	17,719,000	1,209,000	1,310,000	1,807,000	20,270,000	10,359,000	3,302,000	1,919,000	459,000	846,000	340,000	530,000	626,000					0	1,500,000	0	8,500,000	0	0	5,458,000	13,888,000	2,734,000	10,639,000	5,924,000	34,743,000	2,001,000	13,044,000	17,316,000	15,400,000	12,752,000	-101,000	10,352,000	9,012,000	12,134,000	-237,000	1,091,000	7,128,000	8,591,000	2,778,000	6,301,000	7,884,000	6,575,000	15,065,000	6,738,000	2,945,000	548,000	16,797,000	760,000	4,289,000	3,781,000	1,223,000	3,450,000
proceeds from maturity of short-term investments	53,285,000	50,860,000	32,360,000	5,380,000	4,140,000	9,067,000	14,544,000	7,461,000	17,275,000	12,201,000	8,465,000	0	0	0	24,830,000	30,005,000	2,500,000	55,000,000	136,750,000	155,400,000	297,005,000	220,000,000	483,845,000	458,359,000	332,647,000	511,183,000	271,515,000	55,850,000	54,325,000	33,762,000	24,000,000	21,835,000	30,052,000	5,180,000	30,171,000	35,122,000	48,401,000	34,267,000
cash outflow on pelthos transaction
cash paid for investment in primrose bio				0	0	0	-998,000	-14,000
cash paid for palvella notes receivable				0	0
cash paid for the agenus transaction				0	0
cash paid for apeiron acquisition, net of cash received				0
cash paid for invios investment				0
net cash from investing activities	-353,445,000	-10,667,000	4,894,000		-46,507,000	-54,759,000	-3,775,000		-19,503,000	7,556,000	10,549,000	-7,284,000	19,176,000	37,851,000	113,881,000	-35,713,000	-18,217,000	-382,202,000	332,071,000	-26,757,000	308,536,000	-63,179,000	169,517,000	265,803,000	94,777,000	275,302,000	-78,252,000	-586,738,000	-33,581,000	-36,174,000			-30,666,000	-86,727,000	5,078,000	18,217,000	-79,760,000	-11,477,000	-26,365,000	-72,223,000	-2,797,000	-1,711,000	72,000	610,000	-998,000	-1,003,000	-245,000	-3,692,000	-34,000			-242,000	3,945,000	-2,279,000	-137,000	453,000	-23,169,000	1,028,000	8,276,000	1,356,000	3,880,000	12,074,000	13,052,000	-4,231,000	3,873,000	10,960,000	-3,597,000	-26,010,000	-5,777,000	20,879,000	-9,649,000	6,323,000	326,284,000	199,746,000	-3,744,000	-2,132,000	2,995,000	5,120,000	11,055,000	-10,318,000	-39,575,000	-18,479,000	6,397,000	-27,767,000	3,071,000	3,471,000	-3,394,000	-102,277,000
cash flows from financing activities:
gross proceeds from issuance of 2030 convertible senior notes
debt discount and payment of debt issuance cost
purchase of 2030 convertible senior notes hedge
proceeds from issuance of warrants																										0	0															1,000
repurchase of common stock																																																																		0	0	0	-1,613,000															0	0	0	-15,867,000
proceeds from common stock issuance, net of commissions and fees
payments under finance lease obligations	-6,000	-7,000	-7,000	-6,000	-10,000	-4,000	-5,000
payments to cvr holders												-585,000	456,000	0	-1,416,000	0	0	0	-525,000	0	-1,800,000	0																												0	-3,500,000	0	-4,549,000
net proceeds from stock option exercises and espp	25,742,000	8,239,000	4,222,000	19,337,000	21,395,000	9,552,000	15,304,000	6,526,000	3,387,000	9,142,000	3,393,000	1,401,000	820,000	664,000	347,000	4,279,000	1,900,000	558,000	909,000	1,129,000	421,000	141,000	213,000	739,000	1,904,000	1,323,000	7,011,000	2,933,000	8,916,000	653,000	1,494,000	2,015,000	355,000	1,807,000	2,126,000	1,469,000	1,013,000		1,949,000	4,649,000	781,000
taxes paid related to net share settlement of equity awards	-219,000	-145,000	-8,891,000	-1,935,000	-125,000	0	-3,076,000	-257,000	-103,000	-32,000	-4,155,000	-2,218,000	-96,000	-60,000	-5,862,000	-115,000	-2,000	-52,000	0	0	-1,429,000	-1,512,000	-13,000	2,000	-2,895,000	-108,000	-223,000	363,000	-3,797,000	-5,942,000	-90,000	-2,020,000	-2,022,000	0
proceeds from pelthos investors	0
net cash from financing activities	409,645,000	14,995,000	-4,747,000		55,080,000	9,491,000	12,182,000	5,315,000	3,270,000	-67,757,000	-775,000	-5,298,000	-40,829,000	-59,442,000	-170,421,000	4,164,000	-385,000	-27,529,000	-3,706,000	-5,000	-279,305,000	-83,693,000	-211,312,000	-37,591,000	-152,576,000	-347,085,000				-7,255,000	1,404,000	-5,000	-1,667,000	-2,094,000	1,629,000	1,469,000	511,000	1,470,000	1,460,000	4,649,000	781,000	-28,995,000	162,319,000	-3,058,000	-241,000	-2,663,000	-2,048,000	-2,359,000	-9,388,000	3,235,000	1,439,000	82,000	-840,000	52,000	2,000	5,000,000	24,945,000	-178,000	-41,000	52,000	8,000	87,000	-100,000	-90,000	-3,585,000	-201,000	-331,000	-385,000	-2,093,000	-4,581,000	-10,430,000	-277,263,000	-35,425,000	32,695,000	179,000	386,000	41,000	-24,000	-842,000	-153,000	818,000	6,477,000	3,747,000	4,619,000	48,294,000	4,342,000	-16,303,000	131,085,000
effect of exchange rate changes on cash and cash equivalents	-400,000	2,292,000	1,058,000	-1,548,000
net increase in cash and cash equivalents			-24,318,000	8,688,000	45,480,000	-31,954,000	27,139,000																			-39,211,000	7,747,000	100,435,000	30,404,000	-12,119,000	-27,484,000						-66,135,000	3,658,000	-14,468,000	-57,528,000	5,563,000	-20,460,000	166,126,000	1,560,000	1,338,000	8,368,000	-2,652,000	886,000	-7,344,000	5,335,000	-1,839,000	-892,000	2,736,000			-2,592,000	2,687,000												-17,269,000				245,510,000								-41,354,000		6,528,000	-13,972,000	48,754,000			19,246,000
cash and cash equivalents at beginning of period	0	0	72,307,000		0	0	22,954,000																					0	20,620,000		0	0	18,752,000		0	0	97,428,000		0	0	160,203,000		0	0	11,639,000		0	0	12,381,000		0	0	7,041,000		0	0	3,346,000		0	0	16,032,000		0	0	28,753,000		0	0	76,812,000		0	0	158,401,000		0	0	66,756,000		0	0	92,310,000	0	59,030,000		0	0	42,423,000
cash and cash equivalents at end of period	71,707,000	19,680,000	47,989,000		45,480,000	-31,954,000	50,093,000																					100,435,000	51,024,000		-27,484,000	49,582,000	10,641,000		25,230,000	30,057,000	31,293,000		-14,468,000	-57,528,000	165,766,000		166,126,000	1,560,000	12,977,000		-2,652,000	886,000	5,037,000		-1,839,000	-892,000	9,777,000		-1,190,000	-2,592,000	6,033,000		561,000	-809,000	4,044,000		1,611,000	-1,371,000	4,920,000		-17,376,000	-30,366,000	59,543,000		-34,310,000	-300,300,000	403,911,000		-31,586,000	-8,193,000	49,808,000		17,008,000	-18,376,000	50,956,000	-23,638,000	65,558,000		48,754,000	11,269,000	12,979,000
gain on derivative instruments		71,000	174,000			-1,500,000	-196,000
losses from equity method investment in primrose bio				1,245,000	1,194,000	8,030,000	2,352,000
fair value adjustment to primrose bio securities investments				0	29,000
changes in operating assets and liabilities:
purchase of castle creek derivatives
cash paid for debt issuance costs		-2,000	-71,000	-118,000	-210,000	-57,000	-41,000
net decrease in cash and cash equivalents, including cash and cash equivalents classified within assets held for sale
less: net increase in cash and cash equivalents classified within assets held for sale		-2,739,000	-78,000
net decrease in cash and cash equivalents																																	-8,111,000		25,230,000																								561,000	-809,000	-11,988,000		1,611,000	-1,371,000	-23,833,000		-17,376,000				-34,310,000				-31,586,000	-8,193,000	-16,948,000		17,008,000								-29,444,000
amortization/accretion of premium (discount) on investments			-839,000
changes in operating assets and liabilities, net of acquisitions:
net increase in cash and cash equivalents, including cash and cash equivalents classified within assets held for sale			-24,240,000
gain on sale of pelican								0
gain on debt extinguishment												0	-866,000	-1,794,000	-1,532,000		128,000		0	0	-659,000
changes in operating assets and liabilities, net of acquisitions and dispositions:
other economic rights																						0	0
income taxes receivable and payable
cash paid for equity method investment - nucorion
cash paid for novan acquisition, net of restricted cash received								0
net proceeds from viking share collar and viking share put
net cash from (provided by) investing activities
net cash transferred to omniab at omniab separation
repayment at maturity/repurchase of 2023 notes								0	0
cash paid for transaction costs related to omniab transactions
proceeds from bond hedge settlement
net cash from (used) in financing activities
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental disclosure of cash flow information
interest paid													101,000	679,000	359,000		3,000																											102,000	110,000		321,000	254,000	991,000	598,000	552,000	671,000	631,000	714,000												57,000	43,000	51,000	78,000	231,000	44,000	90,000	1,146,000	4,509,000	339,000	4,427,000	517,000	5,852,000	361,000	4,880,000	328,000	5,001,000	300,000	4,930,000	207,000	4,532,000	132,000	151,000
taxes paid													6,610,000				168,000																																		0	-2,000	17,000	12,000												45,000	3,000	91,000	1,000	2,075,000	1,641,000	3,613,000	1,042,000
acquisitions:
fair value of tangible assets acquired, net of cash and restricted cash received
goodwill
intangible assets
financial royalty assets
liabilities assumed
net cash paid for acquisitions
supplemental schedule of non-cash investing and financing activities:
accrued primrose transaction costs
addition of right-of-use assets and lease liabilities
accrued royalty from financial royalty assets
accrued purchases of financial royalty assets
accrued debt issuance costs
accrued fixed asset purchases										392,000	140,000		-174,000	1,226,000	2,574,000		198,000
unrealized gain on available-for-sale investments, net of tax
depreciation and amortization of intangible assets					8,994,000	8,853,000	8,765,000		8,611,000	9,495,000	9,499,000		13,478,000	13,266,000	13,655,000		12,723,000	13,046,000	4,776,000	4,447,000	3,422,000
amortization of premium on investments					-138,000	-430,000	-157,000		-279,000	-377,000	-282,000		31,000	-7,000	51,000
loss on derivative assets
purchase of short-term investments					-31,554,000	-24,441,000	-77,634,000		-18,273,000	-49,125,000	-39,864,000		-580,000	-282,000	-38,190,000		-20,762,000		-290,000	-169,352,000	-167,374,000		-401,312,000	-233,507,000	-1,047,767,000		-412,507,000	-646,826,000	-98,957,000		-80,839,000	-50,930,000	-73,352,000		-23,217,000	0	-49,892,000		-51,356,000
purchase of property and equipment					-596,000	-408,000	-105,000		-487,000	-203,000	-2,414,000		-4,329,000	-6,588,000	-4,875,000		-1,772,000
proceeds from atm sales, net of commissions and fees
purchase of financial royalty assets						-1,731,000	-2,443,000
operating activities
gain short-term investments
amortization of commercial license and other economic rights																-221,000	-110,000	-230,000	-228,000	-225,000	2,958,000
adjustment to credit loss reserves of commercial license rights
impairment loss of commercial license rights								0
investing activities
purchase of commercial license rights																																		0	-4,000			0	0							0	0
proceeds from commercial license rights								69,000	136,000	83,000	130,000
net cash (used) provided in investing activities
financing activities
net cash transferred to omniab at separation
cash paid for omniab transaction costs
repurchase of warrants
net increase in cash, cash equivalents, and restricted cash
cash paid during the year:
acquisition:
deferred tax asset
net cash paid for novan
accrued royalty from commercial license rights
accrued commercial license rights purchases
accrued inventory purchases										-106,000	2,752,000		-1,485,000	8,855,000	306,000		-7,727,000																														-770,000
unrealized gain on available-for-sale investments
amortization of commercial license rights									-69,000	-435,000	-379,000		27,000	-179,000	-11,000
cecl adjustment to commercial license rights
(gain) income from short-term investments									13,184,000	-3,991,000	-39,533,000
other current assets																														3,000	85,000	-431,000	745,000	567,000	620,000	-645,000	16,000	489,000	24,000	-907,000	445,000	189,000	-479,000	-254,000	118,000	553,000	-301,000	-225,000	-157,000	186,000	1,012,000	-221,000	-462,000	319,000	205,000	-265,000	4,605,000	-3,953,000	88,000	-113,000	47,000	-1,081,000	-275,000	106,000	802,000	3,903,000	-1,595,000	586,000	2,048,000	-2,212,000	-231,000	388,000	3,459,000	4,605,000	12,212,000	-10,092,000	-144,000	-3,078,000	252,000	4,152,000	637,000	519,000	46,000	-622,000	-553,000	3,913,000	760,000	-4,473,000
proceeds from convertible bond hedge settlement																	2,083,000
payments for omniab transaction costs													-3,965,000
net decrease in cash, cash equivalents and restricted cash									-8,587,000				-1,164,000	-9,713,000	-4,529,000
cash, cash equivalents and restricted cash at beginning of period									0	0	45,006,000		0	0	19,522,000		0		0	0	72,273,000		0	0	119,780,000
cash, cash equivalents and restricted cash at end of period									-8,587,000	-60,283,000	88,728,000		-1,164,000	-9,713,000	14,993,000		1,423,000		341,220,000	-2,371,000	118,257,000		-48,087,000	167,031,000	107,369,000
cash paid for equity method investment												0	0	0	-750,000			0				0
supplemental disclosure of cash flow information:
supplemental schedule of non-cash activity:
unrealized gain on afs investments, net of tax										-32,000	49,000
repurchase of 2023 notes													-37,646,000	-59,947,000	-163,356,000		-2,379,000		0	0	-203,210,000
payments under financing lease obligations											-13,000		-15,000	-14,000	-13,000		0
net increase in cash, cash equivalents and restricted cash											43,722,000						1,423,000		341,220,000	-2,371,000	45,984,000		-48,087,000	167,031,000	-12,411,000
gain from sale of vernalis r&d
income taxes receivable
cash paid for acquisition, net of cash and restricted cash acquired
proceeds on sale of vernalis r&d
repayment of debt																						0				-195,889,000	0															-2,000	-2,417,000	-3,511,000	-3,436,000	-3,362,000	-3,291,000	-3,219,000	-9,714,000	0	-1,500,000	0	-8,500,000									0	0	0	-3,443,000					0	0	0	-37,750,000
share repurchases																																																						0	0	0	-55,000
payments to convertible bond holders for warrant purchases																	-1,987,000
unrealized loss on afs investments													6,000	-35,000	-114,000		-14,000
restricted cash in other current assets
gain from sale of promacta license																						0	0	0	-812,797,000
loss on debt extinguishment
proceeds from sale of promacta license																						0	0	0	812,797,000
payments to convert holders for bond conversion																						0
net decrease in cash, cash equivalents, and restricted cash
effect of exchange rate changes on cash																			110,000	9,000	-169,000	171,000	-95,000	-123,000	130,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
operating lease liabilities
cash paid for acquisition, net of cash acquired																						0												2,000	0	351,000	-92,855,000
share repurchase																			0	0	-73,287,000		-181,189,000	-38,332,000	-151,585,000		0	-50,832,000	-1,895,000
accrued financing lease payment
amortization of premium (discount) on investments																			309,000	368,000	830,000				-1,818,000					-169,000	132,000	2,000	-46,000
royalties recorded in retained earnings upon adoption of asc 606																										0
proceeds received from repayment of viking note receivable																														0				0	0
gross proceeds from issuance of 2023 convertible senior notes																										0	0
payment of debt issuance costs																										0	0															0
purchase of convertible bond hedge																										0	0															0
supplemental schedule of non-cash investing and financing activities
unrealized gain on afs investments																																												-5,127,000	8,222,000		806,000
purchase of fixed assets recorded in accounts payable
income from short-term investments
net cash from (used in ) operating activities																			12,745,000
repayment of 2019 notes
payments to convertible bond holders for bond conversion
income tax receivable																				4,592,000	4,081,000
cash paid for acquisition
gain from investment in viking																					25,456,000		10,520,000	12,365,000	-17,293,000
realized gain on sale of short-term investment																														-460,000	-123,000	-182,000	-66,000	-576,000	-1,174,000			-615,000	-1,486,000	-949,000	447,000	-297,000	-273,000
(gain) loss on equity investment in viking
non-cash change in estimated fair value of contingent liabilities																							-222,000	-419,000	1,403,000		907,000	1,770,000	960,000		1,336,000	826,000	140,000		957,000	332,000	1,306,000		-2,301,000	7,274,000	3,000		1,619,000	1,313,000	1,948,000	3,965,000	532,000	-2,741,000	1,841,000	2,841,000
depreciation and amortization																							3,779,000	3,695,000	5,086,000	3,297,000	5,408,000	3,011,000	3,002,000	4,133,000	2,017,000	2,585,000	2,979,000	2,968,000	2,934,000	2,813,000	2,575,000	687,000	644,000	646,000	650,000	659,000	661,000	669,000	668,000	656,000	668,000	669,000	670,000	749,000	638,000	662,000	678,000	691,000	750,000	785,000	564,000
amortization of discount on investments																							-1,454,000												179,000	11,000	320,000		107,000
amortization of other economic rights																							4,765,000
changes in operating assets and liabilities, net of effects from acquisition:
income tax payable																							-30,884,000	-66,542,000	113,997,000
gross proceeds from issuance of 2023 notes
less: income from discontinued operations
income from continuing operations																														-7,010,000	8,429,000	6,058,000	5,079,000	-3,126,000	645,000	-5,763,000	5,877,000					6,732,000	776,000	1,287,000	2,097,000	1,869,000	1,965,000	3,694,000	1,304,000	2,586,000	-707,000	-4,066,000	-487,000	5,502,000	-3,901,000	-914,000	9,486,000	2,348,000	-11,854,000	-291,000	-2,989,000	2,569,000	1,051,000	-4,475,000	-7,482,000
change in fair value of the convertible debt receivable from viking and warrants
change in derivative asset and liability fair value
other long term assets																																																				39,000	175,000	39,000	-4,000	110,000	460,000		41,000	43,000	-456,000		1,000	10,265,000	-202,000
contingent liabilities																										25,000
purchase of viking common stock and warrant
purchase of common stock in equity method investment																																		0
payments to cvr holders and other contingency payments																										0	0			0	0	0	-4,998,000	-1,722,000	-1,420,000	-189,000	-5,446,000	-1,799,000	-1,278,000	-416,000	-3,247,000	-1,557,000
stock issued for acquisition, net of issuance cost
stock and warrant received for repayment of viking notes receivable
change in fair value of viking warrants
(gain) / income from investment in viking
accounts payable, accrued liabilities and other																											-5,497,000
cash and cash equivalents and restricted cash at beginning of period
cash and cash equivalents and restricted cash at end of period
payments to cvr holders and other contingent payments
stock-based compensation																												4,812,000	4,555,000	8,998,000	5,248,000	4,624,000	6,045,000	5,203,000	5,331,000	4,241,000	4,118,000	2,947,000	2,836,000	3,761,000	2,914,000	2,475,000	3,702,000	3,026,000	2,067,000								709,000	705,000	950,000	1,244,000	452,000	311,000	557,000	833,000	624,000	924,000	741,000	880,000	820,000	820,000	940,000	851,000	996,000	584,000	866,000	576,000	5,554,000	1,357,000	1,938,000	1,229,000	814,000
change in fair value of the viking convertible debt receivable and warrants																												-7,702,000	-748,000		-503,000	153,000	-76,000		-154,000
(gain) / income from equity investments																												-32,506,000	-21,183,000
royalties recorded in retained earnings upon adoption of asu 606																												0	32,707,000
proceeds received from repayment of commercial license rights																															0
net cash from provided by financing activities																												613,529,000	3,224,000
less: gain from discontinued operations																																				0	731,000									0	0	2,397,000	191,000	-1,523,000	0	1,799,000	1,871,000	0	-1,000	0	4,000	2,155,000	12,000	7,000	239,000	467,000	749,000	2,807,000	2,366,000
gain on deconsolidation of viking
loss on equity investment in viking
reduction of cash due to deconsolidation of viking
gain on disposal of assets																																		0
income from equity method investment
other long-term assets																																			11,000	-1,000	-41,000		52,000	-307,000	-291,000		-1,014,000	-255,000	24,000		50,000	57,000	66,000
purchase of viking common stock and warrants																																			0
income from viking																																1,247,000	1,083,000
net cash provided (used) in investing activities
non-cash milestone revenue
restricted cash																																									661,000
net cash from operating activities of continuing operations																																										10,246,000	3,735,000	4,008,000	2,577,000	12,034,000	-359,000	6,937,000	2,720,000	2,522,000	-560,000	-732,000	-169,000	7,017,000	-1,055,000	-8,045,000	911,000	-1,278,000	-7,673,000	-2,218,000	-16,138,000	-1,434,000	-11,168,000	4,769,000	-22,806,000
net cash from operating activities of discontinued operations																																														0	0	0	-642,000	-350,000	-350,000							-22,000	-1,000	1,000	262,000	145,000	-173,000	-1,819,000	-1,315,000
gross proceeds from issuance of 2019 convertible senior notes																																										0
net income including noncontrolling interests																																			645,000	-5,763,000	6,608,000		224,539,000	22,027,000	-89,000		776,000
adjustments to reconcile net income including noncontrolling interests to net cash from operating activities:
accretion of note payable																																							0	2,000	14,000	-3,000	56,000	69,000	100,000	96,000	96,000	83,000	142,000
gain on deconsolidation of viking therapeutics
income from viking therapeutics																																			1,396,000
restricted investments																																							0
proceeds from sale of property and equipment																																							0	0	1,000	0	0				0	0	3,000																		2,000				0
gain on write-off of assets																																											0
purchase of common stock for rsu vesting																																				0	-502,000
realized (gain) loss on sale of short-term investment																																					-406,000
change in fair value of the convertible debt receivable from viking																																					15,000
loss on equity investment in viking therapeutics, inc.																																					1,605,000		2,170,000
write-off of acquired in-process research and development																																																														1,000	0
purchase of viking common stock																																						0	0
net proceeds from stock option exercises																																												453,000	3,195,000	629,000	1,244,000	775,000	326,000
non-cash upfront fee																																											0
gain on deconsolidation of viking therapeutics, inc.																																							0
reduction of cash due to deconsolidation of viking therapeutics, inc.																																							0
(gain) loss on asset disposal
other liabilities																																														5,000	17,000	-293,000	-120,000	469,000				4,994,000	-2,493,000	-836,000	-800,000	360,000	-20,000	245,000	-1,300,000	-5,685,000	4,936,000	-1,395,000	-174,000	1,820,000	-686,000	34,000	84,000	485,000	115,000	555,000	-242,000		5,000	-16,000	-3,000	-135,000	-10,000	-12,000	-2,000	0	-600,000
proceeds from issuance of debt																																																		0	0	0	7,500,000	0	0	5,000,000	25,000,000
proceeds from issuance of common stock																																																				82,000	160,000														25,000	12,000	34,000		260,000	1,232,000	2,857,000		462,000	1,051,000	468,000				773,000		2,733,000
write-off of in-process research and development																																															0
payments to cvr holders and former license holders																																												-50,000	-1,618,000
supplemental schedule of non-cash activity
liability for commercial license rights																																															0
realized (gain) on investment																																													-481,000
loss on write off of assets																																													109,000
accretion of deferred gain on sale leaseback																																																						-425,000	-426,000	-425,000	-426,000	-425,000	-426,000	-426,000	-425,000	-426,000	-20,444,000	-491,000	-491,000					-491,000	-491,000
non-cash lease costs																																																						84,000	0	-45,000	-90,000		9,655,000	-17,000	-47,000		-156,000	239,000	262,000		827,000	0	4,148,000
gain on asset disposal
acquisition of cydex, net of cash acquired																																																						0	0	0	-32,024,000
purchases of property, equipment and building																																																		38,000	-372,000	-242,000	-19,000
proceeds from sale of property, and equipment and building																																																		3,000	4,000	0	13,000
net proceeds from employee stock purchase program
net proceeds from issuance of common stock																																																							2,000			-87,000	-2,000	94,000	18,000	168,000	-6,000	45,000	21,000													18,000	-8,000							554,000	136,000
net proceeds from employee stock purchase plan																																															-1,000
changes in operating assets and liabilities,:
realized gain on investment																																																					-17,000	0	0	29,000	-23,000	-22,000	-21,000	127,000	-691,000
gain on asset write-offs																																																					-10,000							-38,000	-26,000		1,000
acquisition of metabasis, net of cash acquired																																																											0	0	-2,834,000
acquisition of intellectual property																																																											0
principal payments on equipment financing obligations																																																										0	-39,000	-42,000	-10,000	-81,000	-94,000	-135,000	-163,000	-260,000	-356,000	-397,000	-514,000	-544,000	-549,000	-544,000	-532,000	-525,000	-633,000	-699,000	-680,000	-648,000	-698,000	-726,000	-723,000	-656,000	-641,000	-693,000
proceeds received from sale of building and disbursed to neurogen shareholders
common stock released from restriction
adjustments to reconcile net income to net cash from operating activities, including effects of business acquired:
write-off in-process research and development
net cash provide by (used in) investing activities
non-cash change in estimated fair value of contingent value rights																																																				1,153,000	-764,000
net cash (used in) operating activities of discontinued operations																																																					-200,000
net cash provide by (used in) investing activities of continuing operations																																																					3,945,000			453,000	-23,169,000	1,028,000	8,276,000	1,356,000	3,880,000	12,074,000	13,052,000	-4,231,000	3,873,000
net cash from investing activities of discontinued operations
net cash from financing activities of continuing operations																																																					-840,000
non-cash development milestone revenue																																																														0	0
cash acquired from acquisition of neurogen
net cash from financing activities of discontinued operations
issuance of common stock for acquisition
change in estimated fair value of contingent value rights																																																							-222,000	-679,000	1,736,000	-2,440,000	-2,460,000	-3,690,000	-552,000
proceeds from sale of property and equipment and building																																																										0	384,000	-3,054,000	3,259,000	92,000	1,000	0	15,000
purchases of property and equipment and building
net cash from investing activities of continuing operations
impairment and amortization of acquired intangible assets																																																														0
depreciation and amortization of property and equipment																																																										95,000	669,000	703,000	745,000	764,000	781,000	770,000	819,000	238,000	266,000	250,000	298,000	364,000	399,000	447,000	496,000	651,000	829,000	834,000	913,000	945,000	914,000	896,000	969,000	671,000	838,000	610,000	567,000	593,000	681,000	762,000
non-cash lease exit and termination costs
loss on asset write-offs																																																																	-3,000	-30,000	137,000	-30,000	669,000	274,000	10,000	-268,000	1,013,000
restricted indemnity account and other
cash paid for acquisition of metabasis
cash acquired from acquisition of pharmacopeia
acquisition of development stage asset
(gain) loss on asset write-offs
non-cash lease termination costs
non-cash exit and restructuring costs
decrease (increase) in restricted cash and investments
dividend paid																																																																						0	0
dividend received on treasury stock held by company																																																																						0	0
conversion of 6% convertible subordinated notes into common stock:
employee stock option exercises
realized loss on investment																																																															-115,000	-45,000	88,000		125,000	770,000	500,000
amortization of acquired intangible assets																																																																162,000	162,000
gain on sale leaseback
amortization of acquired technology and royalty and license rights
amortization of debt discount and issuance costs																																																																																		241,000	237,000	234,000	229,000	211,000	194,000
non-cash interest expense																																																																										501,000
inventories																																																																						0	0	0	930,000	2,098,000	-2,038,000	40,000	1,484,000	-327,000	180,000	-2,139,000	-1,144,000	-1,982,000	-1,508,000	-2,257,000	-1,199,000	589,000	-554,000	-1,686,000
restricted indemnity account																																																																		-15,000	-39,000	-40,000	-68,000	-101,000	-30,000	61,000	-10,000,000
proceeds from equipment financing arrangements																																																																										0	485,000	147,000	398,000	629,000	0	510,000	880,000	699,000	1,770,000	540,000	323,000	0	251,000	823,000
decrease in other long-term liabilities																																																																										-15,000	-50,000	-29,000	-59,000	59,000	-57,000	-7,000	-30,000				-11,000	-26,000	-36,000
conversion of principal amount of convertible notes																																																																										128,150,000	0	1,000,000	26,100,000
conversion of unamortized debt issue costs																																																																										-995,000	0	-11,000	-351,000
conversion of unpaid accrued interest																																																																										-718,000	0	0	264,000
operating activities:
gain on sale of avinza product line before income taxes																																																																			-122,000	1,156,000	-8,321,000	2,122,000	-6,892,000	-283,000	-310,131,000
(gain) loss on sale of oncology product line before income taxes
amortization of deferred gain on sale leaseback																																																																			-491,000	-491,000	-491,000				-491,000
amortization of acquired technology and license rights																																																																							0	0	909,000		3,108,000	3,570,000	3,570,000		3,570,000	3,570,000	3,236,000	2,737,000	2,736,000		2,735,000
non-cash co-promote termination expense																																																																						0	0	-1,202,000	-207,000
investing activities:
proceeds from sale of avinza product line																																																																			0	0	8,058,000	0	7,500,000	1,461,000	280,400,000
additional proceeds from sale of oncology product line																																																																							0
decrease in restricted cash																																																																								265,000	38,814,000
financing activities:
gain on sale of oncology product line before income taxes																																																																				685,000	-915,000
employee receivable from stock option exercises																																																																								54,000	127,000
declaration of dividend																																																																									252,742,000
proceeds from sale of oncology product line
payment to buy-down ontak royalty obligation																																																																														0	0	-13,000,000	-20,000,000
proceeds from note payable to king
repurchase of company common stock																																																																						-4,075,000	-10,141,000
adjustments to reconcile income to net cash from operating activities:
adjustment to gain on sale of oncology product line before income taxes																																																																							2,138,000	-9,868,000	61,000
gain on sale of investment																																																																														-542,000	62,000
co-promote termination liability																																																																											3,673,000	3,066,000	136,241,000
decrease in restricted cash and investments
gain on sale of oncology product line
non-cash development milestone
gain on sale of equity investment
proceeds from sale of building
repayment of long-term debt																																																																										-11,584,000	-85,000	-84,000	-86,000	-82,000	-79,000	-77,000	-82,000
receipt and retirement of common stock in settlement of pfizer development milestone
receipt of exelixis, inc. common stock upon sale of equity investment in x- ceptor
amortization of debt issue costs																																																																											232,000	229,000	244,000
gain on sale of exelixis stock																																																																											-45,000	-565,000	-343,000
increase in restricted investments																																																																															0				-43,000				-166,000
capitalized portion of payment of lasofoxifene royalty rights																																																																															0	0	-558,000
non-cash impact of the conversion of 6% convertible subordinated notes into common stock:
non-cash interest expense converted into additional paid-in capital																																																																												3,000	57,000
non-cash impact of stock option exercises where cash was received subsequent to quarter-end																																																																													469,000
write-off of x-ceptor purchase right																																																																																				0	0	0	5,000,000
cumulative effect of change in accounting principle
equity in loss of affiliate																																																																																				117,000	285,000	270,000	302,000	339,000
decrease (increase) in restricted investments
payment for avinza® royalty rights																																																																																				0	0	0	-4,133,000
receipt of exelixis, inc. common stock upon sale of equity investment in x-ceptor
amortization of debt issuance costs																																																																															263,000	258,000	254,000
debt conversion expense																																																																																								0
payment for avinza ® royalty rights
payment to extend x-ceptor purchase right																																																																																								0
net proceeds from issuance of common stock and warrants
increase in other long-term liabilities
net proceeds from issuance of convertible notes
conversion of zero coupon convertible senior notes to common stock																																																																																								0
issuance of common stock and notes for acquired technology and license rights
payment for lasofoxifene royalty rights																																																																																		0	-1,120,000
decrease in restricted investments																																																																																					-59,000
amortization of acquired technology, royalty, and product rights
accrual of obligations for acquired technology and product rights
issuance of common stock for debt conversion incentive																																																																																								0
issuance of common stock for acquired technology
principle payments on equipment financing obligations																																																																																						-519,000	-621,000
amortization of acquired technology and licence rights																																																																																							2,752,000
changes in operating assets and liabilities net of effects from sale of manufacturing assets in 2000:
net proceeds from sale of manufacturing assets
accretion of debt discount and interest
amortization of acquired technology
decrease in other assets
principle payments on equipment financing
redemption of convertible debentures
net proceeds from issuance of zero coupon convertible senior notes

The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.